HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): George M. Palatianos Christophoros N. Foroulis Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palatianos, G. M. Articles by Melissari, E. N. Search for Related Content PubMed PubMed Citation Articles by Palatianos, G. M. Articles by Melissari, E. N. Related Collections Extracorporeal circulation

J Thorac Cardiovasc Surg 2004;127:548-554
© 2004 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost

^a Third Department of Cardiac Surgery, Onassis Cardiac Surgery Center, Athens, Greece
^b Department of Anesthesiology, Onassis Cardiac Surgery Center, Athens, Greece
^c Coagulation and Hemostasis Laboratory, Onassis Cardiac Surgery Center, Athens, Greece

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

Received for publication April 29, 2003; revisions received August 13, 2003; accepted for publication August 18, 2003.

^* Address for reprints: George M. Palatianos, MD, Onassis Cardiac Surgery Center, 356 Sygrou Avenue, 176 74 Athens, Greece
palatianos{at}otenet.gr

OBJECTIVE: The objective of this study was to evaluate our protocol for the identification and management of patients with immune heparin-induced thrombocytopenia undergoing cardiac surgery.

METHODS: Among 1518 patients who underwent cardiac surgery between June 1998 and May 2001, 32 (2.1%) presented with platelet counts less than 150,000/mm³ preoperatively or a history of prolonged (>3 days) intravenous exposure to heparin or both. These 32 patients were evaluated with an enzyme-linked immunosorbent assay for antibodies against heparin-platelet factor 4 complex. Platelets of patients with detected antibodies were tested with the prostacyclin analog iloprost for inhibition of heparin aggregation and determination of the inhibiting concentration and corresponding intravenous infusion rate of iloprost. Patients with antibodies received heparin after complete platelet inhibition with iloprost infusion. Hypotension was prevented or treated with intravenous noradrenaline. Ten randomly selected patients with similar preoperative characteristics, no previous extended exposure to heparin, and normal platelet counts served as controls.

RESULTS: Ten of the 32 patients (group A, 31.3%) and none of the controls had antibodies against heparin-platelet factor 4 complex. Patients in group A underwent surgery with iloprost (6-24 ng · kg^-1 · min^-1) and had their blood pressure maintained at greater than 95 mm Hg with norepinephrine infusion (1-4 µg · kg^-1 · min^-1). Operative mortality was zero. There were no thrombotic complications or bleeding requiring exploration. One patient in group A bled 1310 mL/6 hours but did not need exploration. There was no difference in postoperative blood loss and morbidity between groups. Platelet counts were reduced by 12.5% ± 8.7% (group A) and 38.1% ± 15.2% (control) (P < .001) 1 hour postoperatively and reached preoperative values by the fifth postoperative day.

CONCLUSIONS: Immune heparin-induced thrombocytopenia can be detected preoperatively among patients with a low platelet count or a history of prolonged heparin exposure or both. Cardiac surgery can be safely undertaken using iloprost-induced platelet inhibition during heparinization.

This article has been cited by other articles:

				C. M. Dyke, G. Aldea, A. Koster, N. Smedira, E. Avery, S. Aronson, B. D. Spiess, and A. M. Lincoff Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies Ann. Thorac. Surg., September 1, 2007; 84(3): 836 - 839. [Abstract] [Full Text] [PDF]

				J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]

				A. Koster, C. M. Dyke, G. Aldea, N. G. Smedira, H. L. McCarthy II, S. Aronson, R. Hetzer, E. Avery, B. Spiess, and A. M. Lincoff Bivalirudin During Cardiopulmonary Bypass in Patients With Previous or Acute Heparin-Induced Thrombocytopenia and Heparin Antibodies: Results of the CHOOSE-ON Trial Ann. Thorac. Surg., February 1, 2007; 83(2): 572 - 577. [Abstract] [Full Text] [PDF]

				D. B. Cines, J. B. Bussel, R. B. McMillan, and J. L. Zehnder Congenital and Acquired Thrombocytopenia Hematology, January 1, 2004; 2004(1): 390 - 406. [Abstract] [Full Text] [PDF]